To understand who is actually a candidate and what monitoring looks like, see our expert review of whether peptides are safe for weight loss, including who is a candidate, what monitoring matters, and the right questions to ask a licensed provider
The 28.328.7% average weight loss in TRIUMPH-1 and TRIUMPH-4, and the 2.0% HbA1c with 16.8% weight loss in TRANSCEND-T2D-1, are results no approved drug has matched
Eli Lilly announced the topline results in December 2025: in obese participants with knee osteoarthritis, the 12 mg dose delivered a mean weight loss of 28,7% (32,3 kg / 71,2 lbs) at 68 weeks, and the 9 mg dose delivered a 26,4% reduction
The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
Further, it is worth noting that oral route of administration is likely to grow at a relatively higher CAGR
This puts Retatrutide among the most effective weight loss drugs currently being researched
